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Rabbit polyclonal antibodies were raised against synthetic peptides of the bovine leukemia virus envelope glyeoprotein gp51 and tested against 
the full size protein by the Western blotting technique. We show that acetylation ofgp51 by iodoacetamide either maintains or significantly increases 
the antigen-antibody reaction and conclude therefrom that the reactive potential of an anti-peptide antibody may require acetylation of the 
sulfhydryl groups of the blotted protein. 
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1. INTRODUCTION 
Synthetic peptides are commonly used to idel:tify and 
characterize antigenic determinants of protein antigens 
recognized by the cellular and humoral compartments 
of  the immune response. The strategy was applied here 
to the external glycoprotein BLV-gp51 [1,2]. 
Our study involved the assessment of the reactivity of 
anti-peptide antibodies with the full size protein in sero- 
logical tests such as ELISA, RIA and WB. We mostly 
focused attention on the reactivities observed in WB, 
reasoning that a positive reaction implies that the target 
amino acid sequence is accessible and that the recogniz- 
ed structure is a sequential epitope. We show here that 
antigenic determinants of the polypeptide backbone are 
not necessarily available to the antibody even after WB. 
The reactivity of some antibody molecules sharply in- 
creased after reduction of the protein antigen and ace- 
tylation of the sulfhydryl groups. 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis and pro&tction of anti.peptide antibodies 
A panel of 27 synthetic peptides were prepared using the Boc or 
Fmoc procedures [1.2]. They correspond to the following fragments 
ofgp51: amino acids 21-27, 38-57, 39--d,8, 57-67. 59-69, 64-73, 68-87. 
74-83. 78-92 (linear and cyclic), 81-90, 82-91, 84-103, 98-117. 104-- 
123, 119-132, 124-143,142-161,144-1550 144-157, 168-180, 169-188, 
195~205. 219-238, 249-268, 255-268, 260-26~ (the amino acid num. 
bering did not include the signal peptide; as reported in [3]). 
These peptides were conjugated t6 keyhole limpet hemocyanin, 
Abbreriations: BLV, bovine leukemia virus: ELISA, enzyme-linked 
immunosorbent assay; WB, Western blotting: RIA, radioimmunoas- 
say; Mono A, monoclonal a,~tibody against site A. 
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emulsified with Freund adjuvant and injected via the intradermal 
route in rabbits. ELISA antibody titers were determined using as 
antigens I00 ng of peptides adsorbed onto the walls of the well. Titers 
are expressed as the inverse of the serum dilution for which the optical 
density was twice that of the negative control (preimmune serum)J2]. 
2.2. lVestern blotting 
BLV particles were the sources of antigens. In some experiments, 
partially purified gp51 was also used [4]. 
The protein sample was boiled for 3 min in 409 ml of buffer (Tris- 
HCI 15 raM, pH 6.8; SDS 2%: 2-mercaptoethanol 3%; Bromophenol 
blue 0.005%: glycerol 10%). For the iodoacetamide treatment, he 
protein sample was boiled for 3 rain in 300 ml of buffer (Tris-HCl 0.2 
M, pH 8.3; SDS I%: DTT 0.5%: EDTA 1 raM; Bromophenol blue 
0.005%; glycerol 10%). After cooling, a 100 ml solution of iodoaeeta- 
mide (15 mg of the reagent) was added and incubation was resumed 
for 1 h at room temperature in the dark. lmmobilon (Millipore) strips 
on which electrophoretically fraetionated BLV antigens (+_0.5 mg of 
gp51 per strip) had been blotted were incubated for 30 rain in phos- 
phate buffer saline (PBS; sodium phosphate 0.01 M: NaCI 0.15 M. pH 
7.4) containing 2% of bovine serum albumin to block non-specific 
sites. Strips were then incubated overnight at 4°C with anti-peptide 
antiscra (1:30) or with purified anti-gp51 monoclonal antibodies [5] 
(1:100) in PBS containing 0.2% Tween 80. Strips were washed with 
PBS/Twecn 80 0.2% and then with TBST buffer (Tris-HCl 0.01 M, pH 
7.8; Tween 20 0.05%; NaCI 150 raM) before a 1 h incubation with goat 
anti-rabbit (for antisera) or goat anti-mouse (for monoelonal ntibod- 
ies) immunoglobulins conjugated to alkaline phosphatasc (1:1130), WB 
reactivity was revealed, after extensive washings with TBST buffer, 
using a substrate containing 3,3 mg of NBT (Nitroblue tetrazolium) 
and 5 mg o1" BCIP (3-bromo-4-chloro-3-indolyl-phosphate (toluidine 
salt)) in 10 ml of AP buffer (Tris-HCI 10 raM. pH 9.5; NaCI I00 raM; 
MgCI, 5 raM). 
3, RESULTS 
ELISA antibody titers obtained with the 27 peptides 
mentioned above were reported in previous papers [1,2] 
and some are recalled in Table I for a few illustrative 
purposes. From Table I and Fig. I, it is apparent hat 
antibodies to peptides 142-161 and 255-268 gave a sig- 
nificant reaction in the classical WB test; antisera to 
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Table I
Western blot analysis of gp51 antigen with anti-peptide antibodies 
Rabbit number peptide or MAb code Amino acid sequence anti-peptide 
antibody titer 
Western blotting reactivity 
without iodoaceta- with iodoacetamide 
mide treatment treatment 
14 82-91 PYVGADRFDC 1 090 000 
15 81-90 CPYVGADRFD 14 580 
17 84-103 VGADRFDCPHWDNASQADQG >3 300 000 
20 74-83 TYDCEPRCPY 3 300 000 
21 169-188 LNQTARAFPDCAICWEPSPP >3 300 000 
99 168-180 LLNQTARAFPDCA 3 300 000 
92 142-161 KIPDPPQPDFPQLNSDWVPS >9 900 000 
89 68-87 GARAMVTYDCEPRCPYVGAD >9 900 000 
93 219-238 NSSSFNTYQGWHHPSQRLLF 4 900 000 
2664 255-268 STV$SAPPTRVRR 44 000 
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- + + +  
- +++ 
++ +++ 
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+ + 
+++ +++ 
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Note: +++++. strong reaction: +++, ++, good reaction; +, weak reaction; -, no reaction. 
peptides 68-87 and 219-238 were only weakly positive. 
In contrast, iodoacetamide treatment revealed excellent 
WB reactivity for previously negative sera such as anti- 
peptides 82-91, 84-103, and 168-180. Anti-81-90 serum 
became slightly positive whilst the reaction encountered 
with anti 142-161 was definitely increased. By compari- 
son, the anti-74-83 and 169-188 sera are illustrative of 
the behavior of the other 19 anti-peptide sera; they re- 
mained u~areactive in WB of the entire gp51 even after 
acetylatic;n of sulfhydryl groups. The reactivity of the 
anti-peptide antibodies, as observed after antigen treat- 
ment with iodoacetamide, cannot be considered as non- 
specific since all preimmune sera remained negative 
after iodoacetamide treatment, as shown on Fig. 1 for 
three of them (Rabbits 14. 92.21, lines BI). 
4. DISCUSSION 
Previous studies [1,2] and more recent observations 
with new anti-peptide antibody systems indicated that 
only two regions of gp51 are well recognized by rabbit 
anti-peptide sera in classical WB. The first region is the 
carboxylic end of the protein (peptide 255-268)[1]; the 
second (142-161) corresponds to a putative hinge be- 
tween the NH2 and COOH moieties of gp51 [2]. Both 
regions seem to be particularly accessible ven on the 
native envelope protein. 
Among the 6 sera that are presented in Table I and 
that did not react in classical WB, 3 became strongly 
positive after iodoacetamide treatment, he 3 others ei- 
ther slightly improved (anti-81-90) or remained nega- 
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Fig. 1. Western blot analysis of BLV gp51 antigen with rabbit sera and monoclonal antibodies. Before running the gel BLV-gp51 was subjected 
to SDS-reducing agent denaturation followed (+) or not ( - )  by iodoacetamide treatment, The numbers at the top identify the rabbit antiserum; 
BI represents serum belbre immunization (prei,nmune serum), AI serum after 3 injections of peptide (anti-peptide antibodies): Mono A was used 
as a positive control, 
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Fig. 2. Schematic representation f the gp51 polypeptide backbone. The positions of eysteine (C) residues, potential N-glycosylation sites (N) and 
selected anti-peptide antisera (identified by the rabbit number (14. 15 •..) are indicated. 
tive (anti-74-83 and -169-188). It is of probable signifi- 
cance to note that in the 3 cases (anti-82-91, -84-103, 
-168-180) where a sharp change in antigen-antibody 
reaction was noticed, one C residue was present in the 
peptide sequence (Table I and Fig. 2). In the 2 cases 
where no reactivity was observed, whether acetylation 
was performed or not, a cysteine was also present in the 
peptide. Of  course, acetylation of  a C residue involved 
in a S-S bond will strongly contribute to the denatura- 
tion of the protein and make the corresponding region 
more amenable to react with anti-peptide antibody. In 
the cases where iodoacetamide treatment did not allow 
or increase recognition of  the full size protein by the 
anti-peptide antibody, it can be surmised that the 
epitope recognized in the peptide encounters structural 
constraints in the protein. Sugar side chains are obvious 
candidates to account for the lack of  antibody reactivity 
(Fig. 2) as they amount o ,0,0% of the overall molecular 
weight of gp51 [4]. 
Such considerations are just speculations. They will 
be testable experimentally once the tridimensional or- 
ganization of  gp51 will be available. 
In practical terms, we draw the investigators' atten- 
tion to the fact that WB does not imply full denatura- 
tion of the protein 'and free access to any part of the 
protein backbone. Iodoacetamide treatment either 
keeps unchanged or significantly increases the reactivity 
ofanti-peptide antibodies with the relevant region of the 
blotted protein. In no case did we experience a reduc- 
tion of  that reactivity; in all cases also the reactivity of 
preimmune rabbit sera remained negative after gp51 
acetylation. 
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